Cetuximab administered biweekly has comparable efficacy to a weekly dosing schedule for patients with metastatic colorectal cancer (mCRC), according to results from a study assessing real-world overall survival (OS) in this patient population.
These results were presented at the virtual 2021 ASCO Gastrointestinal Cancers Symposium.
“Cetuximab 250mg/m2 weekly after an initial dose of 400mg/m2 is approved for treatment of K-Ras wild-type mCRC. In real world, 29% of patients received cetuximab 500mg/m2 biweekly,” explained Himani Aggarwal, MA, MPhil, PhD, Eli Lilly and Company (Indianapolis, IN), and colleagues.
This study compared real-world overall survival (OS) associated with biweekly versus weekly dosing of cetuximab for mCRC in the US.
The Flatiron Health electronic health record database was used to identify patients with mCRC who received cetuximab plus FOLFIRI/FOLFOX/irinotecan, or cetuximab monotherapy as first-, second- or third-line therapy from January 1, 2012 to December 31, 2019. Patients were split into groups according to the frequency in which they received cetuximab treatments (weekly vs biweekly).
The study found that patients with mCRC receiving cetuximab achieved similar OS rates, regardless of whether these treatments were administered weekly or biweekly.—Marta Rybczynski
Aggarwal H, Han Y, Lin Cui Z. Real-world data on overall survival associated with biweekly versus weekly cetuximab among metastatic colorectal cancer (mCRC) patients in the United States. Presented at: the virtual 2021 ASCO Gastrointestinal Cancers Symposium; January 15-17, 2021. Abstract 33.
